In conclusion, this real-world study emulating a target clinical trial shows that among a national cohort of patients enrolled at the VHA with moderate to advanced CKD, use of GLP1-RA was associated with lower annual rate of acute healthcare utilization, lower all-cause mortality, and lower kidney events as compared to treatment with DPP4i. The gene discussed is GLP1R; the disease is chronic kidney disease.